UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K	
CURRENT REPORT	

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 24, 2024

UNIVERSAL HEALTH REALTY INCOME TRUST (Exact name of Registrant as Specified in Its Charter)

Maryland 1-9321 23-6858580
(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

Universal Corporate Center 367 South Gulph Road King of Prussia, Pennsylvania (Address of Principal Executive Offices)

19406

(Zip Code)

Registrant's Telephone Number, Including Area Code: (610) 265-0688

Not Applicable (Former Name or Former Address, if Changed Since Last Report)

			_					
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):								
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)							
	□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)							
	□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))							
	Pre-commencement communications pur	suant to Rule 13e-4(c) under the Exc	change Act (17 CFR 240.13e-4(c))					
	heck mark whether the registrant is an emer ule 12b-2 of the Securities Exchange Act of		Rule 405 of the Securities Act of 1933 (§ 230.405 of this					
Securities reg	gistered pursuant to Section 12(b) of the Act	t:						
	Title of each class	Trading Symbol(s)	Name of each exchange on which registered					
Shares of	beneficial interest, \$0.01 par value	UHT	New York Stock Exchange					
Emerging growth company □								
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box								

Item 2.02 Results of Operations and Financial Condition.

On October 24, 2024, the Trust made its third quarter, 2024 earnings release. A copy of the Trust's press release is furnished as exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
99.1	Press release dated October 24, 2024.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

Exhibit Index

Exhibit Number	Description
99.1	Press release dated October 24, 2024.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

UNIVERSAL HEALTH REALTY INCOME TRUST

Date: October 24, 2024 By: /s/ Charles F. Boyle

Name: Charles F. Boyle

Title: Senior Vice President and Chief Financial Officer

UNIVERSAL HEALTH REALTY INCOME TRUST

Universal Corporate Center 367 S. Gulph Road P.O. Box 61558 King of Prussia, PA 19406 (610) 265-0688

FOR IMMEDIATE RELEASE

CONTACT: Charles Boyle

Chief Financial Officer

(610) 768-3300

October 24, 2024

UNIVERSAL HEALTH REALTY INCOME TRUST REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS

Consolidated Results of Operations - Three-Month Periods Ended September 30, 2024 and 2023:

KING OF PRUSSIA, PA - Universal Health Realty Income Trust (NYSE:UHT) announced today that for the three-month period ended September 30, 2024, net income was \$4.0 million, or \$.29 per diluted share, as compared to \$3.9 million, or \$.28 per diluted share, during the third quarter of 2023.

The increase in our net income of \$125,000, or \$.01 per diluted share, during the three-month period ended September 30, 2024, as compared to the third quarter of 2023, consisted of the following: (i) an increase of \$451,000, or \$.03 per diluted share, resulting from an aggregate net increase in the income generated at various properties, partially offset by; (ii) a decrease of \$326,000, or \$.02 per diluted share, resulting from an increase in interest expense due primarily to an increase in our average outstanding borrowings and a slight increase in our average borrowing rate.

As calculated on the attached Schedule of Non-GAAP Supplemental Information ("Supplemental Schedule"), our funds from operations ("FFO") were \$11.3 million, or \$.82 per diluted share, during the third quarter of 2024, as compared to \$11.2 million, or \$.81 per diluted share during the third quarter of 2023. The increase of \$124,000, or \$.01 per diluted share, was due primarily to the above-mentioned increase in our net income during the third quarter of 2024, as compared to the third quarter of 2023.

Consolidated Results of Operations - Nine-Month Periods Ended September 30, 2024 and 2023:

For the nine-month period ended September 30, 2024, net income was \$14.6 million, or \$1.05 per diluted share, as compared to \$11.8 million, or \$0.85 per diluted share during the first nine months of 2023.

The increase in our net income of \$2.8 million, or \$.20 per diluted share, during the first nine months of 2024, as compared to the comparable period of 2023, consisted of the following: (i) an increase of \$2.5 million, or \$.18 per diluted share, resulting from an aggregate net increase in the income generated at various properties; (ii) an increase of \$1.9 million, or \$.13 per diluted share, resulting from a reduction in the expenses related to our property located in Chicago, Illinois, including \$1.1 million from demolition expenses incurred during the first nine months of 2023, and \$563,000 related to a property tax reduction recorded during the first nine months of 2024 which related primarily to prior periods, partially offset by; (iii) a decrease of \$1.6 million, or \$.11 per diluted share, resulting from an increase

in interest expense due primarily to increases in our average borrowing rate as well as our average outstanding borrowings.

As calculated on the attached Supplemental Schedule, our FFO were \$36.1 million, or \$2.61 per diluted share, during the first nine months of 2024, as compared to \$33.2 million, or \$2.40 per diluted share during the comparable period of 2023. The increase of \$2.9 million, or \$.21 per diluted share, was due primarily to the above-mentioned increase in our net income during the first nine months of 2024, as compared to the first nine months of 2023.

Dividend Information:

The third quarter dividend of \$.73 per share, or \$10.1 million in the aggregate, was declared on September 4, 2024 and paid on September 30, 2024.

<u>Capital Resources Information:</u>

On September 30, 2024, we entered into a second amended and restated credit agreement which increased the borrowing capacity to \$425 million (from \$375 million previously) and extended the maturity date to September 30, 2028 (from July, 2025 previously). We have the option to extend the maturity date for up to two additional six-month periods.

At September 30, 2024, we had \$347.8 million of borrowings outstanding pursuant to the terms of our \$425 million revolving credit agreement and \$77.2 million of available borrowing capacity as of that date, net of outstanding borrowings.

Sierra Medical Plaza I:

In March, 2023, construction was substantially completed on the Sierra Medical Plaza I, an 86,000 square foot MOB located in Reno, Nevada. This MOB is located on the campus of the Northern Nevada Sierra Medical Center, a hospital that is owned and operated by a wholly-owned subsidiary of UHS, which was completed and opened during April, 2022. The master flex lease agreement in connection with this building, which commenced in March, 2023 and has a ten-year term scheduled to expire on March 31, 2033, covers approximately 68% of the rentable square feet of the MOB at an initial minimum rent of \$1.3 million annually, plus a pro-rata share of the common area maintenance expenses. This master flex lease agreement is subject to reduction based upon the execution of third-party leases. The aggregate cost of the MOB is estimated to be approximately \$35 million, approximately \$30 million of which was incurred as of September 30, 2024.

Vacant Land/Specialty Facility:

Demolition of the former specialty hospital located in Chicago, Illinois, was completed during 2023. The aggregate demolition expenses amounted to approximately \$1.5 million (\$1.1 million of which were incurred during the first and second quarters of 2023 and \$332,000 of which were incurred during the fourth quarter of 2022). In addition, in December, 2023, we sold the vacant specialty facility located in Corpus Christi, Texas.

We continue to market the vacant properties located in Chicago, Illinois and Evansville, Indiana. Future operating expenses related to these properties, will be incurred by us during the time they remain owned and unleased.

Financial Instruments:

In October, 2024, we entered into an interest rate swap agreement on a total notional amount of \$85 million with a fixed interest rate of 3.2725% that we designated as a cash flow hedge. The interest rate swap became effective on October 2, 2024 and is scheduled to mature on September 30, 2028. If one-month term SOFR is above 3.2725%, the counterparty pays us, and if one-month term SOFR is less than

3.2725%, we pay the counterparty the difference between the fixed rate of 3.2725% and one-month term SOFR.

This interest rate swap agreement replaced two interest rate swaps agreements that expired on September 16, 2024 with a combined aggregate notional amount of \$85 million.

General Information, Forward-Looking Statements and Risk Factors and Non-GAAP Financial Measures:

Universal Health Realty Income Trust, a real estate investment trust, invests in healthcare and human-service related facilities including acute care hospitals, behavioral health care hospitals, specialty facilities, medical/office buildings, free-standing emergency departments and childcare centers. We have investments or commitments in seventy-six properties located in twenty-one states.

This press release contains forward-looking statements based on current management expectations. Numerous factors, including those disclosed herein, as well as the operations and financial results of each of our tenants, those related to healthcare industry trends and those detailed in our filings with the Securities and Exchange Commission (as set forth in *Item 1A-Risk Factors* and in *Item 7 - Forward-Looking Statements* in our Form 10-K for the year ended December 31, 2023 and in *Item 7 - Forward-Looking Statements and Certain Risk Factors* in our Form 10-Q for the quarter ended June 30, 2024), may cause the results to differ materially from those anticipated in the forward-looking statements. Readers should not place undue reliance on such forward-looking statements which reflect management's view only as of the date hereof. We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Many of the factors that could affect our future results are beyond our control or ability to predict. Future operations and financial results of our tenants, and in turn ours, could be materially impacted by various developments including, but not limited to, decreases in staffing availability and related increases to wage expense experienced by our tenants resulting from the shortage of nurses and other clinical staff and support personnel, the impact of government and administrative regulation of the health care industry; declining patient volumes and unfavorable changes in payer mix caused by deteriorating macroeconomic conditions (including increases in uninsured and underinsured patients as the result of business closings and layoffs); potential disruptions related to supplies required for our tenants' employees and patients; and potential increases to other expenditures.

In addition, the increase in interest rates has substantially increased our borrowings costs and reduced our ability to access the capital markets on favorable terms. Additional increases in interest rates could have a significant unfavorable impact on our future results of operations and the resulting effect on the capital markets could adversely affect our ability to carry out our strategy.

We believe that, if and when applicable, adjusted net income and adjusted net income per diluted share (as reflected on the Supplemental Schedule), which are non-GAAP financial measures ("GAAP" is Generally Accepted Accounting Principles in the United States of America), are helpful to our investors as measures of our operating performance. In addition, we believe that, when applicable, comparing and discussing our financial results based on these measures, as calculated, is helpful to our investors since it neutralizes the effect in each year of material items that are non-recurring or non-operational in nature including items such as, but not limited to, gains on transactions.

Funds from operations ("FFO") is a widely recognized measure of performance for Real Estate Investment Trusts ("REITs"). We believe that FFO and FFO per diluted share, which are non-GAAP financial measures, are helpful to our investors as measures of our operating performance. We compute FFO, as reflected on the attached Supplemental Schedules, in accordance with standards established by

the National Association of Real Estate Investment Trusts ("NAREIT"), which may not be comparable to FFO reported by other REITs that do not compute FFO in accordance with the NAREIT definition, or that interpret the NAREIT definition differently than we interpret the definition. FFO adjusts for the effects of certain items, such as gains or losses on transactions that occurred during the periods presented. FFO does not represent cash generated from operating activities in accordance with GAAP and should not be considered to be an alternative to net income determined in accordance with GAAP. In addition, FFO should not be used as: (i) an indication of our financial performance determined in accordance with GAAP; (ii) an alternative to cash flow from operating activities determined in accordance with GAAP; (iii) a measure of our liquidity, or; (iv) an indicator of funds available for our cash needs, including our ability to make cash distributions to shareholders. A reconciliation of our reported net income to FFO is reflected on the Supplemental Schedules included below.

To obtain a complete understanding of our financial performance these measures should be examined in connection with net income, determined in accordance with GAAP, as presented in the condensed consolidated financial statements and notes thereto in this report or in our other filings with the Securities and Exchange Commission including our Report on Form 10-K for the year ended December 31, 2023 and our Report on Form 10-Q for the quarter ended June 30, 2024. Since the items included or excluded from these measures are significant components in understanding and assessing financial performance under GAAP, these measures should not be considered to be alternatives to net income as a measure of our operating performance or profitability. Since these measures, as presented, are not determined in accordance with GAAP and are thus susceptible to varying calculations, they may not be comparable to other similarly titled measures of other companies. Investors are encouraged to use GAAP measures when evaluating our financial performance.

(more)

Consolidated Statements of Income
For the Three and Nine Months Ended September 30, 2024 and 2023
(amounts in thousands, except share information)
(unaudited)

	Three Months Ended September 30,			Nine Mont Septem			
		2024		2023	2024		2023
Revenues:							
Lease revenue - UHS facilities (a.)	\$	8,248	\$	8,274	\$ 25,366	\$	24,297
Lease revenue - Non-related parties		14,342		13,926	43,188		40,955
Other revenue - UHS facilities		242		254	682		730
Other revenue - Non-related parties		305		404	1,056		1,177
Interest income on financing leases - UHS facilities		1,357		1,365	4,077		4,096
		24,494		24,223	74,369		71,255
Expenses:							
Depreciation and amortization		7,009		7,012	20,624		20,479
Advisory fees to UHS		1,386		1,332	4,093		3,957
Other operating expenses		7,609		7,854	 22,115		23,625
		16,004		16,198	46,832		48,061
Income before equity in income of unconsolidated limited liability		_		_	_		
companies ("LLCs") and interest expense		8,490		8,025	27,537		23,194
Equity in income of unconsolidated LLCs		300		314	956		953
Interest expense, net		(4,793)		(4,467)	(13,920)		(12,340)
Net income	\$	3,997	\$	3,872	\$ 14,573	\$	11,807
Basic earnings per share	\$	0.29	\$	0.28	\$ 1.06	\$	0.86
Diluted earnings per share	\$	0.29	\$	0.28	\$ 1.05	\$	0.85
Weighted average number of shares outstanding - Basic		13,807		13,790	 13,799		13,784
Weighted average number of shares outstanding - Diluted		13,849		13,822	13,835	_	13,811

(a.) Includes bonus rental on McAllen Medical Center, a UHS acute care hospital facility, of \$765 and \$725 for the three-month periods ended September 30, 2024 and 2023, respectively, and \$2,306 and \$2,219 for the nine-month periods ended September 30, 2024 and 2023, respectively.

Schedule of Non-GAAP Supplemental Information ("Supplemental Schedule")
For the Three Months Ended September 30, 2024 and 2023
(amounts in thousands, except share information)
(unaudited)

Calculation of Adjusted Net Income

	Three Months Ended September 30, 2024			Three Months Ended September 30, 2023			
	 Amount	Dilu	Per ted Share	I	Amount		Per ed Share
Net income	\$ 3,997	\$	0.29	\$	3,872	\$	0.28
Adjustments	-		-		-		-
Subtotal adjustments to net income	-		-		-		-
Adjusted net income	\$ 3,997	\$	0.29	\$	3,872	\$	0.28

Calculation of Funds From Operations ("FFO")

	Three Months Ended September 30, 2024				ed 3		
	Amount	Dilu	Per ited Share		Amount	Dilu	Per ted Share
Net income	\$ 3,997	\$	0.29	\$	3,872	\$	0.28
Plus: Depreciation and amortization expense:							
Consolidated investments	7,009		0.51		7,012		0.51
Unconsolidated affiliates	311		0.02		309		0.02
FFO	\$ 11,317	\$	0.82	\$	11,193	\$	0.81
Dividend paid per share		\$	0.730			\$	0.720

Schedule of Non-GAAP Supplemental Information ("Supplemental Schedule")

For the Nine Months Ended September 30, 2024 and 2023

(amounts in thousands, except share information)

(unaudited)

Calculation of Adjusted Net Income

	Nine Months Ended September 30, 2024			Nine Months Ended September 30, 2023			
	 Amount		Per ed Share		Amount		Per ed Share
Net income	\$ 14,573	\$	1.05	\$	11,807	\$	0.85
Adjustments	-		-		-		-
Subtotal adjustments to net income	-		-		-		-
Adjusted net income	\$ 14,573	\$	1.05	\$	11,807	\$	0.85

Calculation of Funds From Operations ("FFO")

	Nine Months Ended September 30, 2024				nths Ended er 30, 2023	
	 Amount	Dilu	Per ited Share	 Amount	Dilu	Per ted Share
Net income	\$ 14,573	\$	1.05	\$ 11,807	\$	0.85
Plus: Depreciation and amortization expense:						
Consolidated investments	20,624		1.49	20,479		1.48
Unconsolidated affiliates	918		0.07	900		0.07
FFO	\$ 36,115	\$	2.61	\$ 33,186	\$	2.40
Dividend paid per share		\$	2.185		\$	2.155

Consolidated Balance Sheets (amounts in thousands, except share information) (unaudited)

	Se	ptember 30, 2024	December 31, 2023		
Assets:					
Real Estate Investments:					
Buildings and improvements and construction in progress	\$	654,154	\$	649,374	
Accumulated depreciation		(280,859)		(262,449)	
		373,295		386,925	
Land		56,870		56,870	
Net Real Estate Investments		430,165		443,795	
Financing receivable from UHS		82,921		83,279	
Net Real Estate Investments and Financing receivable		513,086		527,074	
Investments in limited liability companies ("LLCs")		14,260		9,102	
Other Assets:					
Cash and cash equivalents		6,372		8,212	
Lease and other receivables from UHS		6,995		6,180	
Lease receivable - other		8,580		8,166	
Intangible assets (net of accumulated amortization of \$11.9 million and					
\$12.5 million, respectively)		7,758		9,110	
Right-of-use land assets, net		10,925		10,946	
Deferred charges, notes receivable and other assets, net		16,354		17,579	
Total Assets	\$	584,330	\$	596,369	
Liabilities:					
Line of credit borrowings	\$	347,750	\$	326,600	
Mortgage notes payable, non-recourse to us, net		19,662		32,863	
Accrued interest		736		490	
Accrued expenses and other liabilities		12,690		13,500	
Ground lease liabilities, net		10,925		10,946	
Tenant reserves, deposits and deferred and prepaid rents		10,928		11,036	
Total Liabilities		402,691		395,435	
Equity:		- ,			
Preferred shares of beneficial interest, \$.01 par value; 5,000,000 shares authorized; none issued and outstanding		-		-	
Common shares, \$.01 par value; 95,000,000 shares authorized; issued and outstanding: 2024 - 13,849,424; 2023 - 13,823,899		138		138	
Capital in excess of par value		270,826		270,398	
Cumulative net income		840,634		826,061	
Cumulative dividends		(933,216)		(902,975)	
Accumulated other comprehensive income		3,257		7,312	
Total Equity		181,639		200,934	
Total Liabilities and Equity	\$	584,330	\$	596,369	